Thrombin (Ila)-cleavage of fibrinogen (FBG) t o form polymerized fibrin promotes endothelial cell spreading, proliferation, and von Willebrand factor release, requiring the exposure of the p15-42 domain. Studies reported here indicate that Ilacleavage of fibrinopeptide B enhances exposure of a heparin binding domain at the /315-42 neo-N-terminus of fibrin. Crossed immunoelectrophoresis showed heparin-induced mobility shifts indicative of complexing with FBG and with N-terminal CNBr fragments of FBG (NDSK) and of fibrin (Ila-NDSK), but no evidence of heparin complexing with FBG lacking Bp1-42 or with FBG fragments D and E was seen. Elution from heparin-agarose with a linear gradient of NaCl showed that bound portions of both intact FBG and D fragments eluted below physiologic salt concentrations, whereas E3 fragments lacking BPI-53 did not bind. NDSK bound with higher affinity than did intact FBG, whereas binding of Ila-NDSK was maximal in this system. Binding of fibrin(ogen1 t o heparin agarose was saturable as well as inhibitable in a dose-dependent manner with both FBG and heparin. Scatchard analysis indicated a single class of binding site, with dissociation constants (kd) of 0.3 pmol/L for EPARIN BINDING domains (HBDs) are found in a number of adhesive glycoproteins involved in extracellular matrix-cell interactions, including fibronectin (FN),'" laminin: thrombospondin,5*6 and von Willebrand f a~t o r .~ Specific heparin binding peptides of these glycoproteins promote cell adhesion, spreading, and focal contact assembly.'" Only C-terminal BPIy chain fragments of fibrinogen (FBG) were purported to contain HBDs.~ We hypothesized that HBDs reside in the central, N-terminal domain of fibrin(ogen) due to the clustering of basic residues within Bpl-42 displaying a positive charge density similar to the HBD consensus sequence.' Mohri et a1' were unable to detect an HBD within Bpl-42, perhaps due to the presence of a V8 protease cleavage site between pGlu*' and PAlaZ6, the cleavage of which would destroy the integrity of a Bpl-42 HBD. Therefore, we sought to determine whether the central domain of fibrin(ogen), particularly residues p15-42, constitutes a HBD.
Ila-NDSK, 0.8 pmol/L for NDSK, and 18 pmol/L for FBG. Immobilized fibrin had twofold more heparin binding sites than did immobilized FBG and required a 5.5-fold higher concentration of heparin t o inhibit by 50% the binding of labeled heparin. Together, the results indicate that Ila-cleavage results in enhanced exposure of two heparin binding domains (HBDs) with approximately threefold higher affinity in fibrin than in FBG. Synthetic peptidep15-42 showed highest binding t o heparin-agarose followed by Bpl-42, whereas peptides p18-31, p18-27, and p24-42 did not bind. Thus, the primary structure of p15-42 is required for specificity of heparin binding. Basic residues within the p15-32 region segregate primarily to one side of an a-helix in a helical wheel diagram, as is typical for authentic HBDs. Desulfated heparin and heparan sulfate bound more fibrin(ogen) than did other proteoglycans; however, heparin bound sixfold more Ila-NDSK than NDSK. These results confirm that fibrin binds t o heparin with higher affinity than does FBG and that fibrin binding is not solely dependent on charge interactions of p15-42 with the negatively charged glycosaminoglycan.
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observations. First, thrombin (Ira)-cleavage of FBG to form fibrin promotes endothelial cell (EC) spreading,"' proliferation," and von Willebrand factor release.'* These interactions require the exposure of the p15-42 domain. Second, both the primary structureI3 and secondary c~nformation'~ of p1S-42 are highly conserved across species, whereas the fibrinopeptide B primary structures are not.I3 Third, an EC surface glycoprotein of 130 kD was identified that binds to synthetic peptide p IS-42, suggesting the presence of a receptor for fibrin on EC." Fourth, the C-terminal FN HBD interacts with heparan sulfate proteoglycan syndecan 4 to mediate focal adhesion formation by cells that are prespread on substrates with RGD-cell binding domains.*,' Finally, y-thrombin cleavage of the matrix protein vitronectin (VN) alters its conformation to expose a masked HBD.".I7
Heparin has important clinical application in the prevention of thrombosis by modulating various enzymes of the clotting and fibrinolytic Moreover, heparan sulfate proteoglycans are essential cofactors in receptor-growth factor interactions, cell-cell recognition systems, and cellmatrix adhesion processes.'~7.'6.'7,26-zK Thus, knowledge regarding the location of an HBD exposed on fibrin may have significant impact on the interpretation of studies regarding the interaction of heparin with fibrin during clotting, fibrinolysis, or fibrin-cell interactions. The data presented here support the hypothesis that fibrin p15-42 HBDs play an active role in heparin or heparan sulfate modulation of the hemostatic balance, cell-matrix interactions, and wound healing.
MATERIALS AND METHODS

Materials.
Human FBG was purchased from Kabi Vitrum (Franklin, OH). Purified FBG lacking residues 1-42 of the BD chain (desB@l-42-FBG, also known as FBG-325) was kindly supplied by Dr A. Budzynski (Temple University, Philadelphia, PA). FBG plasmic fragments D and E were from Crystal Chemicals (Chicago, CNBr cleavage of jbrin(ogen). N-terminal disulfide knot (NDSK) and IIa-cleaved NDSK (IIa-NDSK) fragments were prepared as de~cribed.~' IIa-NDSK was used to mimic soluble fibrin. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed as described."
Crossed immunoelectrophoresis (CIEP). Trace antibodies to FN and to other serum proteins were removed from polyclonal antibody (PoAb) antihuman FBG by affinity chromatography over a column 2051 of human serum proteins supplemented with purified human FN coupled to CNBr-Sepharose CL-4B. After protein A-Sepharose chromatography, the purified IgG was designated PoAb anti-FBG' ").
Agarose gels (1 % in 25 mmol/L Tricinel80 mmol/L Tris, pH 8.6/1% calcium lactate/O.O2% sodium azide) were poured on GelBond film (FMC BioProducts, Rockland, ME). Each well was loaded with fibrin(ogen) preincubated for 60 minutes at room temperature (RT) with or without heparin (as described in the figure legend^).^." Electrophoresis in the first dimension was at 250 V constant voltage in 0.02 mol/L barbital buffer, pH 8.6, for 1 hour. Each sample lane cut from the first dimension gel was applied to the cathode side of the second dimension gel consisting of 1 % agarose with PoAb anti-FBG'"' at l mg/mL gel. The proteins were electrophoresed into the second dimension at 250 V for 20 hours.
Saturation and inhibition of binding of fibrin(ogen) to heparinagarose. FBG, NDSK, and IIa-NDSK were labeled with canierfree Na[lZ51] (Dupont-NEN, Boston, MA) using Iodo-Gen (Pierce Chemical, Rockford, IL). 33 The specific activity varied between 2.5 and 92.4 pCi/nmol. The binding assay was performed essentially as de~cribed.'~ Nonspecific binding was determined in the presence of 100 molar excess heparin or unlabeled FBG. Specific binding was expressed after the subtraction of nonspecific binding from the total binding: free ligand was calculated by subtracting the amount bound from total ligand. The best fit of experimental points was obtained using LIGAND from Biosoft (Ferguson, MO). Competitive inhibition of 150 nmol/L FBG binding to heparin-agarose was performed using heparin from 0.032 to 100 pmol/L.
Saturation and inhibition of binding of heparin to immobilized jbrin(ogen). FBG and fibrin were immobilized on microtiter plate wells as described,'" except that the FBG (FN-free) solution was l mg/mL FBG instead of 3 mg/mL. After washing and blocking in 5% ovalbumin/PBS for 1 hour at 37°C. increasing amounts of heparin-BSA-biotin were added to wells and incubated 1 hour at RT. After washing, the amount of heparin-BSA-biotin bound was detected with a streptavidin-horseradish peroxidase system. Equal amounts of FBG and fibrin were bound in the solid phase as determined by enzyme-linked immunosorbent assay (ELISA) with PoAb antihuman FBG. Efficiency of IIa-cleavage was detected by ELISA with antifibrin p15-42 MoAb T2G1 compared with anti-FBG Bpl-42 MoAb 18C6. Competitive inhibition of heparin-BSA-biotin bind- 5 ClEP shift factor was determined from the cross-immunoelectrophoresis data shown in Fig 3A through C. The relative distance of migration (R,) of the peak (center) from the origin (well) was determined by dividing the distance of peak migration by the total distance of migration of the dye front in the gel. The ClEP shift factor represents the degree of shift in anodal migration due to protein complexing with heparin, and was calculated as (R, + heparin)/(R, -heparin). No shift in migration in the presence of heparin results in a factor of 1.0.
For personal use only. on October 27, 2017. by guest www.bloodjournal.org From ing to immobilized fibrin(ogen) was performed using 12.5 pglmL heparin-BSA-biotin in the presence of increasing doses of heparin.
Heparin-agarose uffiniry chromatography. Heparin-agarose columns (2.5 mL bed volume) were washed with column buffer (IO mmolL Tris-HCI, pH 7.4). Fibrin(ogen) ( I mL at 300 pglmL) was applied to the column at 5 m m , washed with 12.5 mL column buffer, and eluted with a I O mL linear gradient of 0 to 0.5 moln NaCl in column buffer at 20 mm.' The conductivity of every other fraction was measured in milliosmols and then converted to millimoles per liter of NaCI. Synthetic peptides (net charge), ie, BPI-42 ( + l ) , 015-42 (+3), P24-42 (O), P18-31 ( + l ) , and P18-27 (0). were chosen based on the charge density of basic (B) residues to other (X) residues of XBBBXXBX, as described for an HBD consensus sequence? The primary structure of BPI-42 is QGVNDNEEGFFS-ARGHRPLDKKREEAPSLRPAPPPISGGGYR. The HBD peptide of the B1 chain of laminin (RwlYVVLPRPVCFEKGMNTVRWfl)' was chosen as a positive control HBD peptide. Peptides (5 mglmL) were bound to heparin-agarose and eluted with a 0 to 1.0 molL linear gradient of NaCI.
Solid-phase binding ofjibrin(ogen) to hepurin. Heparin, heparan sulfate, and desulfated heparin (20 pglmL) were bound to polystyrene microtiter plates. After washing and blocking, FBG, NDSK, or Ha-NDSK (200 pglmL) was added to appropriate wells (n = 3) and incubated for 2 hours at RT. Heparin bound protein was detected with IO pglmL PoAb anti-FBG"'N".35
RESULTS
SDS-PAGE and ELISA. Each preparation of fibrin(ogen)
used in this study was tested to assess the degree of enzymatic (Ha, plasmin, and protease 111) or chemical (CNBr) cleavage. Both FBG and FBG-325 were analyzed, reduced, by SDS-PAGE ( Fig 1A) and by ELISA ( Table 2 ). The FBG starting material was free of contaminating FN, and minimal y-y dimer formation was observed. Limited degradation of the Aa chain was observed, as is normally the case in pooled plasma. The BP chain was intact in the FBG starting material ( Fig 1A and Table 2 ). The majority of BPI-42 was cleaved by protease 111 to produce the lower molecular weight (325 kD) FBG-325. However, about 10% of the BP chain was not cleaved, leaving fibrinopeptide B and BPI-42 sequences intact (Fig 1A and Table 2 ). One major band was observed for both NDSK and h-NDSK by SDS-PAGE ( Fig IB) ; however, some heterogeneity was noted. Most likely, the heterogeneity of NDSKs was due to variability in CNBr cleavage at the C-terminal boundary of the central domain, which does not alter the primary structure of the BP1-42 or P15-42 domains. The heterogeneity of Ila-NDSK resulted additionally from incomplete IIa-cleavage in that trace amounts of fibrinopeptide B were detected with MoAb I8C6 (Table 2 ). Plasmin-cleaved FBG fragment D was composed of fragments D,, D*, and D3 (Fig 1B and Table l) , and ELISA of FBG E fragments with MoAbs T2G1 and 18C6 showed that the preparations were composed mostly of the late cleavage fragment E3, which is missing residues BPI-53 (Table 2) .3s
Heparin-jhrin(ogen) complex formation. To determine whether fibrin(ogen) formed complexes with heparin, ClEP was performed. FBG showed an anodal migratory shift in the presence of heparin, whereas FBG-325 incubated with heparin showed no migratory shift (Fig 2A and 
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of the plasmin-cleaved FBG preparations. In the presence of heparin, Ha-NDSK showed a greater anodal migratory shift than did NDSK, suggesting that Ila-cleavage enhances the availability of a specific HBD (Fig 2C) . The two peaks of precipitin line obtained in the second dimension with IIa-NDSK in the presence of heparin, coupled with the degree of shift in anodal migration, suggest a population of NDSK heterodimerically cleaved with Ita, which would leave one intact fibrinopeptide B per molecule ( Table 2 ). The results indicate that BPI-42 is required for complex formation with heparin and that IIa-cleavage enhances binding of heparin with the fibrin P15-42 N-terminus. Saturation and inhibition of binding of jbrin(ogen) to heparin-agarose. Scatchard analysis of the binding data was analyzed by the LIGAND program, which suggested a single class of binding sites (Fig 3A through C) with an average kd of 0.8 pmol/L for NDSK, 18 pmol/L for FBG, and 0.3 pnol/L for IIa-NDSK. These results indicate that Ila-NDSK binds heparin with 2.7-fold higher affinity than does NDSK, but that both bind with much higher affinity than intact FBG. The specificity of FBG binding was confirmed by the inhibition of its binding with '*'I-FBG (data not shown) and with heparin (IC5o of 42 mmol/L; Fig 3D) . Saturation and inhibition of binding of heparin to immobilizedjhrin(ogen). Because intact fibrin is insoluble, kd determinations as described above could not be performed. Therefore, a reciprocal binding assay was developed to measure the binding of biotin-tagged heparin to fibrin and FBG immobilized on a solid surface. Heparin-BSA-biotin bound to both immobilized FBG and fibrin in a dose-dependent and saturable manner ( Fig 4A) ; however, maximum binding of heparin at saturation was twofold higher to fibrin than to FBG. These results indicate that IIa-cleavage of FBG resulted in exposure of twice the number of heparin binding sites. Competitive inhibition of heparin binding showed that the amount of heparin that caused a 50% inhibition in the binding of the biotin-BSA-heparin (IC'o) to immobilized fibrin was 5.5-fold greater (ICs0 = 6.6 pmol/L) compared with the amount required to inhibit binding to FBG (IC50 = 1.2 pmol/L; Fig 4B) , suggesting higher affinity of fibrin than FBG for heparin. (Table 3) . suggesting a requirement for the presence of BPI-42 to support FBG binding to heparin. Further support was obtained using the NDSKs of FBG and IIa-fibrin; greater than 95% of both NDSK and IIa-NDSK bound to heparinagarose ( Fig 5A and Table 3) . Comparison of the molarity of salt required to elute the peak fractions of each preparation showed that both FBG-325 and D fragments eluted below physiologic salt concentrations. Intact FBG eluted at below physiologic salt (1 20 mmol/L) as well, suggesting that FBG binding to heparin is not physiologically relevant. The reduced binding to heparin-agarose and elution of fragments D and FBG-325 with low salt indicated weak complexing of these fragments with heparin, which was borne out by the absence of detectable complex formation by CIEP (Fig  2) . NDSK bound with higher affinity (200 mmol/L) than intact FBG; however, IIa-NDSK (350 mmoVL) bound to heparin-agarose with the highest affinity (Fig 5B) . with each peptide contributing a net +3 charge (Fig 6) . FBG peptide Bpl-42 with a lower net positive charge (+ 1) also bound to heparin-agarose, but to a lesser extent (67.2%). The unbound fraction of PI-42 was reapplied and none of the pl-42 bound, indicating the fraction of peptide is nonbinding and that the heparin-agarose column was not overloaded. Very little ,618-31 bound (8.5%) to heparin-agarose, even though this peptide has the same net charge as BPI-42 of + l. Furthermore, neither neutral peptide 018-27 nor p24-42 bound to heparin-agarose ( 4 % ; Fig 6) , indicating that charge is not the sole determining factor for the binding of BP chain N-terminal sequences to heparin. Significant binding was obtained with peptides having net charges of +3 and + 1, whereas peptides with + 1 net charge and neutral peptides containing basically charged Arg and Lys (p18-31 and p18-27, respectively) did not bind. We propose that residues Bpl-42 constitute, at least in part, an FBG HBD; similarly, P15-42 constitute a fibrin HBD. Peptides p18-27, p18-31, and P24-42 did not bind to heparin-agarose (Fig 6) , suggesting further that residues within p15-23, and perhaps p32-42, are essential for conferring the specificity and proper conformation on the p chain N-terminus to mediate fibrin (ogen) binding to heparin (Table 4) .
First
Dimension First Dimension
SpecQicity offibrin(ogen) binding to proteoglycans and glycosaminoglycans. Comparison of fibrin(ogen) binding to heparin, chondroitin sulfate, demtan sulfate, heparan sulfate, and keratan sulfate indicated that fibrin(ogen) bound with the highest affinity to heparin ( d a t a not shown). When the binding of FBG, NDSK, and plasmin fragment D to heparin, heparan sulfate, and desulfated heparin fixed to a solid surface was compared, little difference in binding to the various heparin derivatives was observed (Fig 7) . In contrast, when the binding of Ha-NDSK to all three heparin derivatives was compared, the results indicated maximal binding to heparin followed by desulfated heparin and heparan sulfate, which is sulfated to a lesser degree than heparin (Fig 7) . IIa-NDSK showed fourfold to sixfold higher binding to all three heparin derivatives than was observed for FBG and for NDSK (Fig 7) . Very little binding to any of and p15-42 of fibrin constitute, at least in part, the HBDs of FBG and fibrin, respectively. Mohri et aIx showed that HBDs are localized to regions of the Bp and y chains in the C-terminal domain of FBG that are generated by V8 protease cleavage. Our data confirm the presence of these HBDs in that D fragments bound to heparin-agarose, albeit with much lower affinity, than did the NDSKs of both FBG and fibrin. The FBG Ply HBDs differ considerably from HBDs described for other adhesive glycoproteins. The capacity of the FBG Ply HBD to bind to heparin was not eliminated by reduction and alkylation: as would be expected.' In addition, the synthetic peptide with neutral charge that corresponds to the platelet recognition domain 7398-41 1, yGQQHHLGGAKQAGDV, inhibited FBG binding to heparin-Sepharose..' This peptide neither bears resemblance to the structures of other known HBD peptides nor does it share similarity to the consensus sequence described for HBDs.~ In contrast, the structure of P15-42 of fibrin bears considerable likeness to the HBD consensus sequence (Table   4 and Fig 8 ) . ' The strength of the complex formed between heparin and fibrin(ogen) fragments was shown to vary. Ila-NDSK bound with higher affinity than did NDSK to heparin-agarose, as shown by their elution profiles and dissociation constants. FBG E3 fragments lacking 01-53.'' did not bind to heparinagarose. FBG-325 lacking BPI-42, FBG D fragments lacking BPI-133, and intact FBG exhibited weaker binding to heparin-agarose because all eluted at less than 120 mmol/L NaCI. Compared with binding of FBG, tighter binding of NDSK ( I .6-fold) and IIa-NDSK (2.9-fold) to heparin-agarose was observed. A comparison of the kd shows that IIa-NDSK bound to heparin-agarose with 2.7-fold higher affinity than did NDSK, with both binding with much higher affinity than intact FBG. These data are compatible with one class of binding site located on the NDSK within BPI-42. Also, the kd are in the same range determined by others for soluble FBG and fibrin monomer. Fibrin monomer (5.7 pmol/L) exhibited a 3.5-fold higher affinity than FBG (20 pmol/L)'y for heparin, consistent with our data showing that Ila-cleavage of FBG exposes a higher affinity HBD in fibrin. In addition, the low affinity of intact FBG for heparin (1 8 prnoll L this study; 20 pmol/L per Hogg and Jackson") suggests that the heparin binding site in the D domainx," is unlikely to be physiologically relevant compared with the HBD at the fibrin(ogen) BP chain N-terminus.
However, it is unlikely that the 30-to 60-fold enhancement of binding of fibrin(ogen) NDSKs to heparin compared 
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with intact FBG reflects the in vivo situation. We hypothesize that, in vivo, the p15-42 domain of FBG is probably inaccessible to heparinheparan sulfate proteoglycans. Subsequent IIa-cleavage and resulting conformational changes occumng during fibrin f~r m a t i o n '~. '~.~"~~ are most likely required to make the p15-42 site available for fibrin-cell interactions involved in hemostasis and wound repair.""' Unfortunately, it is extremely difficult to compare the physiologic soluble FBG to the physiologic insoluble fibrin in binding assays without experimentally manipulating the ligands so that they are either both soluble or both immobilized to a solid surface. It is known that disruption of the rigid coiledcoil region of fibrin(ogen), as would occur by CNBr cleavage, experimentally alters the native conformation by allowing more flexibility in the N-terminus.4" Consequently, CNBr cleavage may partially expose the 015-42 HBD in fibrin(ogen) NDSKs. Similarly, the HBD of VN is exposed by either proteolytic ~leavage'~.'' or chemical denat~ration.~' Immobilization of FBG on a surface also alters native conformation by exposing neo-epitopes not accessible on FBG in s~lution.~' Further, urea treatment of FBG results in partial exposure of the conformational fibrin-p15-42 epitope recognized by T2Gl,".'* which is in close proximity to the fibrin HBD. Fibrin monomer prepared in the presence of GPRP to inhibit polymerization was considered as an alternative li- gand to Ila-NDSK for Scatchard analysis. However, the efficiency of fibrinopeptide B cleavage is accelerated as polymerization of fibrin proceeds, suggesting that polymerization-induced conformational changes facilitate IIa-release of fibrinopeptide Based on this interpretation, we chose not to inhibit fibrin polymerization with GPRP in case this prevented efficient release of fibrinopeptide B, a consideration crucial to our experimental objectives. In addition, when fibrinopeptide B is fully released, fibrin aggregation occurs, even in the presence of GPRP (J.R.S., unpublished data). Therefore, at the higher concentrations of protein required for the Scatchard analysis as performed in this report, the potential for fibrin monomer to become insoluble aggregates would have clouded interpretation of the data. The use of NDSK and IIa-NDSK provided soluble fragments that could never polymerize due to the absence of the complementary "a" and "b" polymerization sites found on y chains of the D fragment.
Therefore, because it is not yet experimentally feasible to compare directly the binding affinities of the physiologic relevant forms of FBG and fibrin and most of the experiments conducted in this and other studies were performed with soluble fragments of fibrin, we developed two additional assays to measure (1) the binding of heparin to intact FBG and to fibrin immobilized to a solid surface and ( 2 ) the binding of fibrin(ogen) fragments to a panel of various To substantiate the hypothesis that the newly exposed HBDs on fibrin have higher affinity for heparin than the same region in FBG, competitive inhibition of heparin binding to immobilized FBG and fibrin was performed. The 5.5-fold stronger binding of heparin to immobilized fibrin is most likely due to a combination of the doubling of the actual number of binding sites and the higher binding affinity of fibrin 015-42 for heparin. Further support for this hypothesis was obtained by kd determinations with the soluble forms of NDSK and Ila-NDSK, which indicate a 2.7-fold increase in affinity after IIa-cleavage. Further, IIa-NDSK bound to desulfated heparin and heparan sulfate to a fourfold to sixfold higher degree than did FBG fragments. These data suggest that, in addition to the charge interaction and primary structure specificity of 015-42, there may be a defined specificity of saccharide structures for heparin binding to 015-42, as is the case for antithrombin Ill binding to a pentasaccharide sequence of heparin?
The ability of heparin to modulate secondary conformation at heparin binding domains of glycoproteins is well described." Heparin binding induces amphiphatic a-helices, segregating basic residues primarily to one side of the helical face, which may serve to lock or stablilize the conformation of the HBD.9 Secondary structure determinations predict that the 019-26 region of fibrin(ogen) forms an a-helix, which after IIa-cleavage may mediate conformational changes that induce the proper folding of the fibrin 0 chain N-terminu~.~~ Basic residues of 015-32 segregate primarily to one side of the helical face in a helical wheel diagram (Fig 8) , forming a region of high positive charge density that compares to authentic HBDs. ' We propose that conformational changes in the 0 chain N-terminus, caused by 1Ia-release of fibrinopeptide B (BflI-14),14.37 enhance the exposure of the HBD in fibrin, thus allowing more avid binding of heparin to fibrin than to FBG. An analogous situation is found for VN, in which y-thrombin cleavage alters its conformation to expose a cryptic HBD."."
Although the significance of heparin binding to domains of fibrin(ogen) has not been documented in vivo, there is a considerable body of in vitro evidence showing that heparin binding to Ila-fibrin monomer in a ternary complex could profoundly affect the regulatory balance between hemostatic and thrombotic events. The effects of heparin on ternary complex formation and IIa-binding to fibrin have been stud- For personal use only. on October 27, 2017. by guest www.bloodjournal.org From the ternary complex VN-IIa-antithrombin 111 to proteoglycans on the apical surface of EC.4h We have data indicating that fibrin fragments, but not FBG, bind to EC by a heparindependent mechanism involving residues 0 1 S-42 (manuscript submitted), which is compatible with the knowledge that fibrin p1S-42 sequences interact directly with the EC cell surface." Also consistent with this is the fact that IIacleavage of fibrinopeptide B is required for fibrin-induced EC capillary tube formation in vitro with fibrin on the apical surface of the EC.47 Moreover, a C-terminal HBD of FN functions in focal adhesion assembly' by interacting with a cell surface heparan sulfate proteoglycan (syndecan 4) in addition to the primary receptor:ligand interaction, which is mediated through either 01-or 03-integrins with the RGDcell binding domain of From these observations, we propose that fibrin(ogen) functions similarly to other heparin binding adhesive glycoproteins in cel1:matrix interactions.
Dual-receptor binding may promote formation of a multimolecular complex, converting an initially low-affinity interaction into a high-avidity complex.
We postulate that lowaffinity cell surface heparan sulfate proteoglycan may interact with the 015-42 HBD of fibrin while the integrin receptor avP3 interacts with the fibrin(ogen) Aa-chain RGD domain. Thus, the interaction of the integrin cell receptor with a matrix protein may lead to adhesion lacking focal contacts that, upon ligation of cell surface heparan sulfate proteoglycan with the HBD, could promote stable focal adhesions and stress fibers,'.' which are indicative of cell proliferation." Alternatively, binding of fibrinP1S-42 to the apical surface of EC (manuscript submitted), presumably via heparan sulfate proteoglycan coreceptors, may induce a migratory phenotype to promote capillary tube formation" during angiogenesis. Together, these observations underscore the importance of elucidating the physiologic mechanism(s) that is involved in mediating fibrin-EC interactions dependent on Ila-induced exposure of the ,B1 S-42 domain."'~''~47
